Featured Research

from universities, journals, and other organizations

Cell death researchers identify new Achilles heel in acute myeloid leukemia

Date:
January 17, 2012
Source:
Walter and Eliza Hall Institute
Summary:
Researchers have discovered that acute myeloid leukemia, an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.

Melbourne researchers have discovered that acute myeloid leukemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1.

The research team at the institute was led by Dr Stefan Glaser, from the institute's Cancer and Haematology division, and Professor Andreas Strasser, joint head of the institute's Molecular Genetics of Cancer division, working in collaboration with scientists from the Australian Centre for Blood Diseases and St. Vincent's Institute of Medical Research in Melbourne, as well as Austrian and American researchers. The research is published in this week's edition of the journal Genes & Development.

AML is the most common type of acute leukemia (rapidly-developing cancers of immature blood cells) in Australia. Some forms of AML occur in children, while other forms are more prevalent in adults over the age of 60. Patients are normally treated with chemotherapy, but even for the least severe forms of AML, the disease returns after chemotherapy in around one-third of cases. Of patients with the most severe forms of AML, fewer than one in six will survive for five years after diagnosis.

The research team determined that treatments that remove the protein Mcl-1 from AML cells can rapidly kill these aggressive cancer cells. Mcl-1 is a so-called 'pro-survival' protein, because it can make cells long-lived. Mcl-1 is part of the 'Bcl-2 family' of pro-survival proteins, many of which are known to be important controllers of cancer development and can render cancer cells resistant to anti-cancer treatments.

The gene for Mcl-1 was first discovered in AML cells, but until now it had not been realised that the Mcl-1 protein was critical for AML cells to live, Dr Glaser said. "Other research has already shown that high levels of Mcl-1 are associated with resistance to chemotherapy," said Dr Glaser. "What we have shown is that without Mcl-1, AML cells rapidly die. This is exciting because it identifies Mcl-1 as a potential target for new anti-cancer medications."

Because of the important role pro-survival Bcl-2 family proteins, including Mcl-1, play in cancer development and in the response of cancer cells to treatment, new classes of medications are being developed to block these proteins, making cancer cells die. One class of these medications, called BH3 mimetics, which inhibit certain pro-survival Bcl-2 family proteins, are currently in clinical trials for the treatment of some forms of leukemia.

Dr Glaser is hopeful that in the future, new treatments for AML will be developed that work by specifically blocking Mcl-1. "We found that many types of AML cells were very dependent on Mcl-1 to survive," he said. "When Mcl-1 was depleted from the AML cells, they rapidly died. Importantly, non-cancerous blood cells were much less susceptible to dying when Mcl-1 was depleted. This means that, if Mcl-1 inhibitors are developed, there may be a 'treatment window' in which AML cells are killed, while normal blood cells that are essential for health can be spared, helping patients recover from the treatment much better. We are optimistic that in the future, Mcl-1 inhibitors may improve the outlook for AML patients, who currently have a very poor prognosis."

This study was supported by the National Health and Medical Research Council, the Leukemia and Lymphoma Society (US), the Victorian Cancer Agency, the Leukaemia Foundation of Australia, the Australian Cancer Research Foundation, the Deutsche Forschungsgemeinschaft (Germany), the Lady Tata Memorial Trust (UK), and the Victorian Government.


Story Source:

The above story is based on materials provided by Walter and Eliza Hall Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. P. Glaser, E. F. Lee, E. Trounson, P. Bouillet, A. Wei, W. D. Fairlie, D. J. Izon, J. Zuber, A. R. Rappaport, M. J. Herold, W. S. Alexander, S. W. Lowe, L. Robb, A. Strasser. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes & Development, 2012; 26 (2): 120 DOI: 10.1101/gad.182980.111

Cite This Page:

Walter and Eliza Hall Institute. "Cell death researchers identify new Achilles heel in acute myeloid leukemia." ScienceDaily. ScienceDaily, 17 January 2012. <www.sciencedaily.com/releases/2012/01/120117145501.htm>.
Walter and Eliza Hall Institute. (2012, January 17). Cell death researchers identify new Achilles heel in acute myeloid leukemia. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2012/01/120117145501.htm
Walter and Eliza Hall Institute. "Cell death researchers identify new Achilles heel in acute myeloid leukemia." ScienceDaily. www.sciencedaily.com/releases/2012/01/120117145501.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
CDC Calls for New Ebola Safety Guidelines

CDC Calls for New Ebola Safety Guidelines

AP (Oct. 20, 2014) Centers for Disease Control and Prevention Director Dr. Tom Frieden laid out new guidelines for health care workers when dealing with the deadly Ebola virus including new precautions when taking off personal protective equipment. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins